Abstract
Cushing’s syndrome is associated with multiple physical manifestations of hypercortisolism that impair patient quality of life. Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat, a potent oral 11β-hydroxylase inhibitor, rapidly normalized and sustained control of mean urinary free cortisol (mUFC) in most patients with CD over a median treatment period of 130 weeks (W).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.